"Falsified Medicines - the Cost to Public Health"

20 June 2013

A recent report by the Alliance for Safe Online Pharmacy – EU ( www.asop.eu) has highlighted the significant cost to the public health purse caused by highly organized criminal activity which results in patients and consumers buying falsified medicines online outside of European Union member state - controlled and regulated health systems.

The report was presented during a round table discussion held on June 19 in the European Parliament and hosted by Member of the European Parliament Bill Newton-Dunn. At any one time there are in excess of 30,000 fake pharmacy web sites aimed at the European population and this equates to in excess of 97% of all online pharmacy web sites.

The report estimated that between 1 billion euros ($1.33 billion) and 3 billion euros is the cost of sales of falsified medicines in Europe in one year and that this number would increase despite all of the extra and successful measures being taken by law enforcement bodies such as INTERPOL and EUROPOL and national law enforcement bodies. ASOP - The Alliance for Safe Online Pharmacy – EU plays a crucial role in bringing together, on a voluntary and collaborative basis, all stakeholders to create an environment that enables patients to buy their medicines online safely (where it is legal to do so).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical